Compare Sibanye Stillwater Ltd (SBSW) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sibanye Stillwater Ltd vs Smith & Nephew plc — how do they compare? Sibanye Stillwater Ltd trades at $10.34 (market cap $7.54B), while Smith & Nephew plc trades at $30.02 (market cap $12.54B). The key difference: Smith & Nephew plc is the larger of the two by market cap, and Sibanye Stillwater Ltd pays the higher dividend (2.93%). Which is the better fit depends on your goals.
| SBSW | SNN | |
|---|---|---|
Market Cap | $7.54B | $12.54B |
Sector | Basic Materials | Health |
52-Week High | $21.12 | $38.70 |
52-Week Low | $7.27 | $28.73 |
Enterprise Value | $9.19B | $15.57B |
Dividend Yield | 2.93% | 2.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Sibanye Stillwater (SBSW) trades at $10.77, up 0.94% with a bullish technical signal. Despite negative profitability metrics, the stock shows attractive valuation with P/E of 4.76 and P/S of 0.94. Recent earnings misses contrast with improved cash flow projections for 2025. Analyst consensus is mixed with 42.9% buy ratings and $14.25 price target, suggesting 32% upside potential.
The stock presents a value opportunity with deep undervaluation but carries significant execution risk. Key catalysts include debt reduction initiatives and commodity price recovery, while persistent negative margins and volatile earnings remain concerns. Institutional sentiment leans cautiously optimistic given the substantial discount to analyst targets.
SNN trades at $29.87, down 0.71% on the day, with a bearish technical signal. The company reported Q2 2026 revenue growth of 1.6%, below expectations, leading to a reduced full-year outlook. Fundamentals show improvement with 2025 revenue of $6.16B and net income of $625M, yielding a 10.08% margin, though recent earnings have been mixed. The balance sheet remains solid with $619M in cash and a debt-to-asset ratio of 29.75% for 2025.
The outlook is cautious due to near-term operational weakness, particularly in U.S. Orthopaedics, offset by innovation in robotics and wound care. Risks include execution challenges and competitive pressures, while analyst sentiment is predominantly Hold. The stock's valuation appears reasonable with a P/E of 20.41, but growth catalysts are needed for significant upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sibanye Stillwater Ltd
Sibanye Stillwater Ltd is a South Africa-focused mining company. The Group currently owns and operates five underground and surface gold operations in South Africa: the Cooke, DRDGOLD, Driefontein, and Kloof operations in the West Witwatersrand region, and the Beatrix Operation in the southern Free State province. In addition to mining, the company owns and manages extraction and processing facilities at its operations, where gold-bearing ore is treated and beneficiated to produce gold dore. The gold dore is further refined at Rand Refinery into gold bars with a purity of at least 99.5% and is then sold on international markets. Sibanye holds a 44% interest in Rand Refinery, global refiners of gold, and the largest in Africa. Rand Refinery markets gold to customers around the world.
Read more on SBSW →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
